Showing 31-40 of 145 results for "".
- FDA Greenlights Restylane Lyft for Hand Rejuvenationhttps://practicaldermatology.com/news/fda-greenlights-restylane-lyft-for-hand-rejuvenation/2457757/The US Food and Drug Administration has approved Restylane Lyft for use on the dorsal hands of people older than 21, making it the first hyaluronic acid (HA) injectable gel approved for this use. Radiesse (Calcium Hydroxylapatite) is also approved for the correction of lost volume in hands. “As w…
- FDA Greenlights Humira Biosim Cyltezo for Multiple Inflammatory Diseaseshttps://practicaldermatology.com/news/fda-greenlights-humira-biosim-cyltezo-for-multiple-inflammatory-diseases/2458073/The U.S. Food and Drug Administration (FDA) approved Boehringer Ingelheim Pharmaceuticals, Inc.’s Cyltezo™, a biosimilar to Humira®, in a pre-filled syringe for the treatment of multiple chronic inflammatory diseases, including: Moderate to severe plaque psoriasis Active psoriatic arthritis Mo…
- FDA Greenlights NDA for New Impetigo Treatmenthttps://practicaldermatology.com/news/fda-greenlights-nda-for-new-impetigo-treatment/2458449/The U.S. Food and Drug Administration (FDA) has accepted Medimetriks Pharmaceuticals, Inc.'s New Drug Application (NDA) for their novel impetigo treatment, ozenoxacin cream, 1%. Ozenoxacin cream is a non-fluorinated quinolone. The Prescription Drug User Fee Act (PDUFA) date for the completion of …
- FDA Greenlights First-Ever OTC Retinoidhttps://practicaldermatology.com/news/fda-greenlights-first-ever-otc-retinoid/2458507/The U.S. Food and Drug Administration (FDA) approved Differin Gel 0.1% (adapalene), a once-daily topical gel for the over-the-counter (OTC) treatment of acne in people 12 years of age and older. Differin Gel 0.1% is the first retinoid to be made available OTC for the treatment of acne, and contains…
- FDA Greenlights Taltz for Psoriasishttps://practicaldermatology.com/news/fda-greenlights-taltz-for-psoriasis/2458635/The U.S. Food and Drug Administration approved the IL-17A blocker Taltz (ixekizumab) for adults with moderate-to-severe plaque psoriasis. Taltz is marketed by Indianapolis, Indiana-based Eli Lilly and Company. Given via 80 mg/mL injection, Taltz’s active ingredient is an antibody (ixekizumab) that…
- Jeremy B. Green, MDhttps://practicaldermatology.com/profiles/jeremy-b-green-md/OKnqv6/
- H. L. Greenberg, MDhttps://practicaldermatology.com/profiles/h-l-greenberg-md/Lkm4Xo/
Burnout: Is Personal Happiness the Answer?
https://practicaldermatology.com/series/the-practical-dermatology-podcast/burnout-is-personal-happiness-the-answer/18191/Physician burnout remains a conversation, and the pandemic dramatically changed the landscape for dermatologists—for better and for worse. Omaha, NE-based Joel Schlessinger, MD, who serves as Chief Cosmetic Surgery Editor of Practical Dermatology® speaks with Las Vegas-based dermatologist H.L. GreenThe Landscape of Vitiligo Treatment
https://practicaldermatology.com/series/updates-vitiligo/the-landscape-of-vitiligo-treatment/24467/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, talks with Lawrence Green, MD, a dermatologist practicing in Rockville, MD, about the landscape of treatments for patients with vitiligo and new therapies that may be coming from ongoing clinical trials.IDAS, LBO Laser System by Quantel Derma
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/idas-lbo-laser-system-by-quantel-derma/19373/IDAS by Quantel Derma - Green Light for Mobile Power. IDAS is the powerful LBO laser system with 532 nm wavelength for vascular indications such as rosacea or telangiectasia and pigmented skin changes. Its 8 watt power make treatments very effective. Due to its robust technology, IDAS has an officia